Evaluating the effectiveness of target therapies for atopic dermatitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study assesses the drug survival rates of approved target therapies for moderate-to-severe atopic dermatitis, including monoclonal antibodies and JAK inhibitors. Patients aged 18 and older who are starting or currently on these therapies will be enrolled, and their clinical and demographic data will be collected during baseline and follow-up visits. The study aims to evaluate the relationship between drug survival and various clinical, laboratory, and pharmacological factors over a 12-month period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 years or older
* Diagnosed with moderate-to-severe atopic dermatitis (EASI\>24)
* Undergoing therapy (retrospective cohort) or undertaking systemic therapy with a biological drug or small molecules
* (for retrospective data) presence of at least one follow-up visit after the start of treatment for which clinical and demographic data were collected at baseline and follow-up visits.
* Signature of informed consent to the study and to the processing of personal data for the research

Exclusion Criteria:

* Patients under 18 years of age
* Patients who have undergone systemic therapy with a biological drug or small molecules for whom the start date of treatment is not available and/or no clinical-demographic data were collected at baseline and at follow-up visits.
* Absence of informed consent to the study and processing of personal data for research purposes.

Where it's running

• fondazione policlinico universitario agostino gemelli IRCCS
  Rome, Italy Recruiting

Study contacts

• Principal investigator: Ketty Peris, Prof — Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Study coordinator: ketty peris, Prof
• Email: ketty.peris@unicatt.it
• Phone: +390630155284

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Roflumilast Cream 0.3% for moderate to severe atopic dermatitis in children, adolescents, and adults

  A cream called roflumilast 0.3% is tested once daily to see if it helps people with moderate to severe atopic dermatitis, compared to a non-medicated cream, across ages 6 and up.

  Recruiting at 4 sites Phase 3 Arcutis Biotherapeutics, Inc. · Birmingham, Alabama and 3 other locations · NCT07916480

• Nocturnal ScratchSense ring: test of automatic scratch detection in adults with itchy skin

  This study tests whether the Replior ScratchSense ring can accurately detect and measure nighttime scratching in adults with itchy skin conditions.

  Recruiting Replior AB · Grenoble · NCT07909967

• ADBest TREAT Registry for adults with atopic dermatitis

  A registry in Germany is collecting real-world data from adults with atopic dermatitis to see how treatments are used and how the disease affects quality of life.

  Recruiting Universitätsklinikum Hamburg-Eppendorf · Hamburg · NCT07904546

• How lebrikizumab affects the skin microbiome and mycobiome in adults with atopic dermatitis

  This study looks at whether lebrikizumab changes the skin bacteria, fungi, and specifically Staphylococcus species, in adults with moderate-to-severe atopic dermatitis.

  Recruiting University Hospital Bispebjerg and Frederiksberg · Copenhagen · NCT07807228

• QX-4533 safety study in healthy volunteers and people with moderate-to-severe atopic dermatitis

  This study tests the safety and tolerability of QX-4533, given as a pill, in healthy adults and in patients with moderate-to-severe atopic dermatitis to see how the drug behaves in the body and what side effects may occur.

  Recruiting Phase 1 QuantX Biosciences US Inc. · Shanghai, Shanghai Municipality · NCT07800104

• Tilrekimig for moderate-to-severe eczema in teens and adults

  A 52-week study will test tilrekimig against dupilumab and a placebo to see if it helps people 12 and older with moderate-to-severe atopic dermatitis.

  Recruiting at 31 sites Phase 3 Pfizer · Birmingham, Alabama and 49 other locations · NCT07783425

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.